Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Neuromyelitis Optica 1Myelitis, Transverse 1Myelitis 1Gastrointestinal Stromal Tumors 1Erectile Dysfunction 1

Interventions

Docetaxel 292Prednisone 241enzalutamide 195Leuprolide 185Radiotherapy 179Abiraterone Acetate 170Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 93abiraterone 83gallium 68 PSMA-11 81Specimen Handling 73darolutamide 67Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 53Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × 4-Aminopyridine × Clear all
NCT03701581 2025-12-17

4-aminopyridine Treatment for Nerve Injury

University of Arizona

Phase 2/3 Recruiting
70 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡